Cite
HARVARD Citation
Goll, G. et al. (n.d.). AB0442 Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a norwegian randomised trial. Annals of the rheumatic diseases. pp. 1383-1384. [Online].